ALKS

27.76

0.43% 0.12

Dopo l'orario di chiusura: 27.76

Alkermes Plc (ALKS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ALKS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$27.64

Aprire:

$27.88

Volume 24 ore:

2.88M

Relative Volume:

1.46

Capitalizzazione di mercato:

$4.63B

Reddito:

$1.48B

Utile/perdita netta:

$241.66M

Rapporto P/E:

19.38

EPS:

1.4325

Flusso di cassa netto:

$480.33M

1 W Prestazione:

-3.04%

1M Prestazione:

-16.28%

6M Prestazione:

+2.93%

1 anno Prestazione:

-17.43%

Intervallo 1D:

$27.41

$28.34

Intervallo di 1 settimana:

$27.03

$28.89

Portata 52W:

$25.16

$36.32

Alkermes Plc Stock (ALKS) Company Profile

Nome

Alkermes Plc

Settore

Healthcare (1116)

Industria

Drug Manufacturers - Specialty & Generic (83)

Telefono

00-353-1-772-8000

Indirizzo

CONNAUGHT HOUSE, DUBLIN 4

Dipendente

2,050

Cinguettio

@alkermes

Prossima data di guadagno

2024-10-24

Ultimi documenti SEC

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALKS Alkermes Plc	27.76	4.63B	1.48B	241.66M	480.33M	1.4325
TAK Takeda Pharmaceutical Co Adr	17.77	56.14B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	115.62	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.03	44.67B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	28.57	33.27B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	536.12	23.50B	3.18B	1.33B	1.04B	27.90

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2025-11-11	Iniziato	Truist	Buy
2025-09-26	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Iniziato	Wells Fargo	Overweight
2025-07-15	Iniziato	Goldman	Buy
2025-06-17	Aggiornamento	UBS	Neutral → Buy
2025-05-28	Iniziato	Needham	Buy
2025-03-13	Iniziato	RBC Capital Mkts	Sector Perform
2025-03-04	Aggiornamento	UBS	Sell → Neutral
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-11-05	Aggiornamento	Stifel	Hold → Buy
2024-06-17	Iniziato	TD Cowen	Buy
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-20	Downgrade	UBS	Neutral → Sell
2023-11-20	Ripresa	JP Morgan	Neutral
2023-10-24	Aggiornamento	Evercore ISI	In-line → Outperform
2023-10-17	Iniziato	UBS	Neutral
2022-11-03	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-14	Aggiornamento	BofA Securities	Underperform → Neutral
2022-08-16	Iniziato	Piper Sandler	Neutral
2022-04-22	Ripresa	Goldman	Buy
2022-04-20	Iniziato	Goldman	Buy
2022-01-27	Aggiornamento	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Iniziato	Citigroup	Neutral
2021-10-07	Aggiornamento	Jefferies	Hold → Buy
2021-09-02	Downgrade	BofA Securities	Neutral → Underperform
2020-10-15	Aggiornamento	Mizuho	Neutral → Buy
2020-07-30	Downgrade	Goldman	Neutral → Sell
2020-02-14	Downgrade	BofA/Merrill	Buy → Neutral
2020-02-14	Reiterato	H.C. Wainwright	Neutral
2020-02-14	Downgrade	JP Morgan	Overweight → Neutral
2020-02-06	Iniziato	Mizuho	Neutral
2020-01-31	Aggiornamento	Wolfe Research	Underperform → Peer Perform
2019-09-05	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Aggiornamento	Goldman	Sell → Neutral
2019-05-31	Iniziato	H.C. Wainwright	Neutral
2019-05-01	Downgrade	Citigroup	Buy → Neutral
2018-12-19	Downgrade	Goldman	Neutral → Sell
2018-12-14	Iniziato	Wolfe Research	Underperform
2018-12-13	Downgrade	Credit Suisse	Outperform → Underperform
2018-11-05	Iniziato	Piper Jaffray	Neutral
2018-08-07	Iniziato	Stifel	Hold
2018-06-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Iniziato	B. Riley FBR, Inc.	Buy
2018-05-16	Aggiornamento	Citigroup	Neutral → Buy
2018-05-11	Iniziato	BofA/Merrill	Buy

Mostra tutto

Alkermes Plc Borsa (ALKS) Ultime notizie

Mar 13, 2026

Is Alkermes (ALKS) Pricing In Its Potential After Recent Share Price Weakness - Yahoo Finance

Mar 13, 2026

Mar 12, 2026

Market Outlook: Will Alkermes plc outperform its industry peers2026 Summary & Long-Term Growth Plans - baoquankhu1.vn

Mar 12, 2026

Victory Capital Management Inc. Has $10.33 Million Stock Position in Alkermes plc $ALKS - MarketBeat

Mar 12, 2026

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program - The Joplin Globe

Mar 12, 2026

Opioid Use Disorder Market Booming with Rapid Growth Through 2033 | Indivior PLC • Alkermes • Orexo AB - openPR.com

Mar 12, 2026

Mar 11, 2026

Alkermes to Present at the Stifel 2026 Virtual CNS Forum - BioSpace

Mar 11, 2026

Mar 09, 2026

Alkermes shares rise after revenue beat and upbeat outlook offsets earnings miss - MSN

Mar 09, 2026

Citigroup Inc. Sells 121,945 Shares of Alkermes plc $ALKS - MarketBeat

Mar 09, 2026

Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case (ALKS)? - Sahm

Mar 09, 2026

Mar 08, 2026

Rhenman & Partners Asset Management AB Buys 55,000 Shares of Alkermes plc $ALKS - MarketBeat

Mar 08, 2026

Neuberger Berman Group LLC Has $4.58 Million Holdings in Alkermes plc $ALKS - MarketBeat

Mar 08, 2026

Why analysts are rating Alkermes (ALKS) a buy - MSN

Mar 08, 2026

Mar 06, 2026

Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch - TipRanks

Mar 06, 2026

Alkermes plc (NASDAQ:ALKS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Mar 06, 2026

Avadel Pharmaceuticals Shares Climb on $2.1 Billion Acquisition by Alkermes - MSN

Mar 06, 2026

(ALKS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 06, 2026

Mar 05, 2026

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - Stocktwits

Mar 05, 2026

Mar 04, 2026

Alkermes (NASDAQ:ALKS) EVP Sells $59,575.86 in Stock - MarketBeat

Mar 04, 2026

Craig Hopkinson Sells 9,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Mar 04, 2026

Christian Todd Nichols Sells 6,000 Shares of Alkermes (NASDAQ:ALKS) Stock - MarketBeat

Mar 04, 2026

Alkermes (ALKS) CEO granted 88,843 restricted stock units in Form 4 - Stock Titan

Mar 04, 2026

Alkermes Reports 2025 Financials, Advances Narcolepsy Pipeline, Announces CEO Succession - Sleep Review

Mar 03, 2026

Mar 02, 2026

Alkermes Pivots Deeper Into Sleep Medicine After Avadel Deal, Details Orexin Phase 3 at TD Cowen - Yahoo Finance

Mar 02, 2026

Alkermes (NASDAQ: ALKS) insider sells common stock via Form 144 - Stock Titan

Mar 02, 2026

Alkermes (ALKS) Rule 144: Insider sale notice for 6,000 shares, $180K - Stock Titan

Mar 02, 2026

5,000-share exercise and multiple sales reported by Alkermes (ALKS) - Stock Titan

Mar 02, 2026

Alkermes at TD Cowen: Strategic Shift to Sleep Medicine - Investing.com

Mar 02, 2026